The Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia Resistant to Previous Therapies

Journal of Blood Medicine - New Zealand
doi 10.2147/jbm.s7284
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Informa UK Limited

Related search

First-Line Treatment of Chronic Lymphocytic Leukemia: Role of Alemtuzumab

OncoTargets and Therapy
OncologyPharmacology
2010English

Complement Dependent Cytotoxicity in Chronic Lymphocytic Leukemia: Ofatumumab Enhances Alemtuzumab Complement Dependent Cytotoxicity and Reveals Cells Resistant to Activated Complement

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2012English

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

ISRN Oncology
2014English

Treatment-Related Acute Myeloid Leukemia in a Chronic Lymphocytic Leukemia Patient: Role of Fludarabine?

Therapeutic Advances in Hematology
Hematology
2015English

Reprint Of: A Review of Cellular Therapies for Chronic Lymphocytic Leukemia

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

Ofatumumab Monotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Final Results From a Pivotal Study

Haematologica
Hematology
2015English

A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.

Blood
BiochemistryImmunologyCell BiologyHematology
2009English

Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia

PLoS ONE
Multidisciplinary
2013English

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (Literature Review)

Oncogematologiya
OncologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy